Tozinameran and BNT 161 combination vaccine(BioNTech/Pfizer)

N/A

Report date: 2026/05/13 09:07:57

Base Information

Drug NameTozinameran and BNT 161 combination vaccine(BioNTech/Pfizer)
Drug Alias NameBNT162b2/BNT161 combination vaccineCombination COVID-19 & Influenza(BioNTech/Pfizer)Tozinameran/BNT-161 vaccine(BioNTech/Pfizer)Tozinameran/qIRV(BioNTech/Pfizer)PF-07926307
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Multivalent vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Influenza, Human
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer IncBiontech Se
China Registration ClassN/A

Develop Information

Active CompaniesNovavaxPfizer IncBiontech Se
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Influenza, Human
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A